Jazz Pharmaceuticals (JAZZ) EBIAT (2010 - 2026)

Jazz Pharmaceuticals has reported EBIAT for 17 years, with the latest figure at $293.1 million in Q1 2026.

• For the quarter ending Q1 2026, EBIAT rose 416.86% year-over-year to $293.1 million; the trailing twelve-month figure through Mar 2026 stood at $29.5 million (down 93.88% YoY), and the FY2025 full-year result was -$356.1 million, down 163.58% from the prior year.
• EBIAT for Q1 2026 stood at $293.1 million, up from $203.5 million in the prior quarter.
• The five-year high for EBIAT was $293.1 million in Q1 2026, with the low at -$718.5 million in Q2 2025.
• Average EBIAT over 5 years is $40.5 million, with a median of $94.2 million recorded in 2023.
• Year-over-year, EBIAT plunged 580.95% in 2022 and jumped 4114.94% in 2023.
• Tracing JAZZ's EBIAT over 5 years: stood at -$240.7 million in 2022, then jumped by 139.11% to $94.2 million in 2023, then jumped by 102.98% to $191.1 million in 2024, then increased by 6.45% to $203.5 million in 2025, then jumped by 44.06% to $293.1 million in 2026.
• The last three EBIAT figures came in at $293.1 million (Q1 2026), $203.5 million (Q4 2025), and $251.4 million (Q3 2025), per Business Quant data.

Peer Comparison